The microbial identification market is expected to reach USD 3.00 Billion by 2022 from USD 2.18 Billion in 2017, at a CAGR of 6.6%.
Seattle, WA -- (SBWIRE) -- 09/27/2017 -- The report "Microbial Identification Market by Product & Service (Instruments, Consumables, Identification Services), Method (Phenotypic, Proteomics-based, Genotypic), Application (Pharmaceutical, Diagnostic, Environmental, Food), End User - Global Forecast to 2022", The microbial identification market is expected to reach USD 3.00 Billion by 2022 from USD 2.18 Billion in 2017, at a CAGR of 6.6%. Factors driving the growth of this market include increasing incidence of infectious diseases coupled with epidemic and pandemic outbreaks, growing concerns about food safety, innovations in microbial identification techniques, and government initiatives and funding supporting microbial identification.
Browse 184 Market Data Tables and 38 Figures spread through 227 Pages and in-depth TOC on "Microbial Identification Market"
Early buyers will receive 10% customization on reports.
Instruments are estimated to account for the largest market share in 2017
On the basis of product and service, the microbial identification market is classified into instruments, consumables, and services. The instruments are expected to lead the global microbial identification market in 2017. Factors driving the growth of this segment include the wide use of instruments across applications and technological advancements, which have led to the launch of innovative products.
Download PDF Brochure:- http://www.marketsandmarkets.com/pdfdownload.asp?id=10702182
The phenotypic methods segment is estimated to dominate the market in 2017
By method, the market is segmented into phenotypic, genotypic, and proteomics-based methods. The phenotypic methods segment is anticipated to account for the largest share of the global microbial identification market in 2017. These methods are cost-effective, easy to perform, and can deliver results rapidly. Therefore, they are widely adopted across industries, which is a major factor responsible for the large share of this segment.
By end user, the hospitals, diagnostic laboratories, and blood banks segment is estimated to command for the largest share of the market during the forecast period
On the basis of end user, the microbial identification market is categorized into hospitals, diagnostic laboratories, and blood banks; food manufacturing companies; beverage manufacturing companies; pharmaceutical companies and CROs; and other end users. The hospitals, diagnostic laboratories, and blood banks segment is estimated to account for the largest share of the global microbial identification market in 2017. The heavy burden of different infectious diseases, along with periodic outbreaks of pandemic and epidemic diseases are the key factors driving the growth of this end user segment.
Request For Sample Pages: http://www.marketsandmarkets.com/requestsample.asp?id=10702182
North America is estimated to command the largest share of the market
Based on region, the microbial identification market is segmented into North America, Europe, Asia, and Rest of the World (RoW). North America is expected to dominate the microbial identification market in 2017. This is attributed to factors like increasing adoption of microbial identification techniques for research purposes; rising prevalence of infectious diseases; growing incidence of foodborne infections, safety concerns; and technological advancements in microbial identification products in the region as compared to other regions.
Key players in the microbial identification market include Becton, Dickinson and Company (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), bioMérieux S.A. (France), Merck KGaA (Germany), Charles River Laboratories International, Inc. (US), Bruker Corporation (US), Shimadzu Corporation (Japan), VWR Corporation (US), Eurofins Scientific S.E. (Luxembourg), GTCR, LLC. (US), QIAGEN N.V. (Netherlands), Liofilchem s.r.l. (Italy), IEH Laboratories & Consulting Group (US), Alcami Corporation (US), Biolog, Inc. (US), Abellon CleanEnergy Limited (India), Alpha Analytical, Inc. (US), NeoGenomics, Inc. (US), Trivitron Healthcare (India), Molzym GmbH & Co. KG (Germany), Dynatec Labs (US), Altogen Labs (US), STERIS plc (UK), and Wickham Laboratories Ltd. (UK).
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
701 Pike Street,
Suite 2175, Seattle,
WA 98101, United States